Hangzhou Tigermed Consulting Valuation
Is 3347 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 3347 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 3347 (HK$32.35) is trading below our estimate of fair value (HK$48.51)
Significantly Below Fair Value: 3347 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 3347?
Key metric: As 3347 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 3347's PE Ratio? | |
|---|---|
| PE Ratio | 55.1x |
| Earnings | CN¥958.67m |
| Market Cap | CN¥48.98b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8x |
| Enterprise Value/EBITDA | 35.3x |
| PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does 3347's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.7x | ||
2269 WuXi Biologics (Cayman) | 20.9x | 17.9% | HK$59.1b |
2268 WuXi XDC Cayman | 46.1x | 27.5% | HK$29.4b |
1521 Frontage Holdings | 45.2x | 64.8% | HK$2.1b |
1093 CSPC Pharmaceutical Group | 10.7x | 2.7% | HK$59.3b |
3347 Hangzhou Tigermed Consulting | 55.1x | 36.1% | HK$49.0b |
Price-To-Earnings vs Peers: 3347 is expensive based on its Price-To-Earnings Ratio (55.1x) compared to the peer average (30.7x).
Price to Earnings Ratio vs Industry
How does 3347's PE Ratio compare vs other companies in the Asian Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 3347 is expensive based on its Price-To-Earnings Ratio (55.1x) compared to the Asian Life Sciences industry average (30.8x).
Price to Earnings Ratio vs Fair Ratio
What is 3347's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 55.1x |
| Fair PE Ratio | 20.6x |
Price-To-Earnings vs Fair Ratio: 3347 is expensive based on its Price-To-Earnings Ratio (55.1x) compared to the estimated Fair Price-To-Earnings Ratio (20.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
3SBio
HK$13.0b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.52
7D
-4.3%
1Y
-26.2%
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a
Consun Pharmaceutical Group
HK$6.8b
Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
1681
HK$8.22
7D
-2.1%
1Y
74.9%